A successful business executive and attorney, Gabriel Holschneider is the founder of the Rainmaker Group, a Mexico City-based consultancy that assists insurance providers in optimizing risk management strategies. Gabriel Holschneider is committed to philanthropic work and supports several charitable organizations, including Boston Children’s Hospital.
The Manton Center for Orphan Disease Research at Boston Children’s Hospital and Alexion Pharmaceuticals, Inc., are working together to provide an accurate and rapid diagnosis for patients suspected of having rare diseases. The Manton Center specializes in decoding and treating rare diseases, and Alexion Pharmaceuticals provides expertise in genomics and data science.
Alexion is offering its 20 Rare Disease Questions (20RDQ) platform, which contains an artificial intelligence engine that assists physicians in diagnosing patients suspected of having a rare disease. Providing doctors with a guided sequence of questions that helps them explore the subtle signs and symptoms of rare diseases, the 20RDQ platform can also be used with genome sequencing to generate a list of genetic variants of rare diseases.
